Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 12
Phase 21

Trial Status

Recruiting1
Terminated1
Other1

Role Distribution

Principal Investigator2
Other Roles1
PI Rate67%

Activity Timeline

Clinical Trials (3)

NCT05289687Phase 2Recruiting
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
T-cell Acute Lymphoblastic Leukemia
StudychairStart date: 2023-05-25
NCT02819804Phase 1Terminated
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic Leukemia+2 more
PrincipalinvestigatorStart date: 2017-08-17
NCT02861040Phase 1Withdrawn
Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Recurrent Adult Acute Lymphoblastic LeukemiaRefractory Adult Acute Lymphoblastic Leukemia
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Marie Bleakley

Fred Hutch/University of Washington Cancer Consortium

Related
4 trials

Shared therapeutic areas:

Recurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRefractory Adult Acute Lymphoblastic Leukemia+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score20%

David Maloney

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
11 trials

Shared therapeutic areas:

Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic Leukemia

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Jordan Gauthier

Fred Hutch/University of Washington Cancer Consortium

Related
5 trials

Shared therapeutic areas:

Recurrent Adult Acute Lymphoblastic LeukemiaRefractory Adult Acute Lymphoblastic Leukemia

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Brenda Sandmaier

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
12 trials

Shared therapeutic areas:

Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic Leukemia

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Hongtao Liu

University of Chicago Comprehensive Cancer Center

Related
4 trials

Shared therapeutic areas:

Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic Leukemia

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Marco Mielcarek

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
5 trials

Shared therapeutic areas:

Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic Leukemia

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Jorge Cortes

M.D. Anderson Cancer Center

Related
8 trials

Shared therapeutic areas:

Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic Leukemia

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Maryam Fouladi

Children's Oncology Group

Related
5 trials

Shared therapeutic areas:

Recurrent Childhood Acute Lymphoblastic Leukemia

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score5%

Srdan Verstovsek

M.D. Anderson Cancer Center

Related
4 trials

Shared therapeutic areas:

Recurrent Adult Acute Lymphoblastic Leukemia

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score5%

Farhad Ravandi-Kashani

M.D. Anderson Cancer Center

Related
7 trials

Shared therapeutic areas:

Recurrent Adult Acute Lymphoblastic Leukemia

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT05289687Phase 2StudyChair

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

T-cell Acute Lymphoblastic Leukemia
Recruiting
NCT02819804Phase 1PrincipalInvestigator

Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic Leukemia+2 more
Terminated
NCT02861040Phase 1PrincipalInvestigator

Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic LeukemiaRefractory Adult Acute Lymphoblastic Leukemia
Withdrawn

All 3 trials loaded